Last reviewed · How we verify
GEN1042
At a glance
| Generic name | GEN1042 |
|---|---|
| Also known as | GEN1042 (DuoBody®-CD40x4-1BB) |
| Sponsor | Genmab |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors (PHASE1, PHASE2)
- A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors (PHASE1)
- A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GEN1042 CI brief — competitive landscape report
- GEN1042 updates RSS · CI watch RSS
- Genmab portfolio CI